Jansen Jan O, Pedroza Claudia, Novelo Luis Leon, Hao Tianyao, DeWildt Gina R, Coton Charles F, Mansoor Kiran, Stephens Shannon W, Marques Marisa B, Stubbs James R, Richter Jillian R, Wang Henry E, Holcomb John B, DeSantis Stacia M
Center for Injury Science, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Pediatrics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y.
Hemorrhage is the most common cause of potentially preventable death after injury. Balanced transfusion with red blood cells, plasma, and platelets (component therapy, CT) has been shown to reduce mortality, and is the standard of care. Low-Titer Group O Whole Blood (LTOWB) is an attractive alternative to CT, but existing evidence comprises observational studies, and a small single center pilot randomized controlled trial, which evaluated a type of whole blood that is no longer in use. The aim of the "Trauma Resuscitation with Low-Titer Group O Whole Blood Or Products" (TROOP) trial is to compare the effectiveness and safety of LTOWB and CT in critically injured patients predicted to require a large volume transfusion.
This is a pragmatic, multicenter, Bayesian, sequential non-inferiority/superiority, randomized clinical trial, performed within 15 level I trauma centers in the United States. We aim to randomize 1,100 injured patients to resuscitation with either CT or LTOWB. The primary outcome is 6-h mortality. Secondary outcomes include 24-h and 30-day or hospital mortality (whichever is earlier); prespecified complications; adjudicated cause of death; time to death; length of stay (ICU and hospital); and hospital-, ventilator- and ICU-free days; the incidence of major surgical procedures; time to hemostasis in those undergoing procedures with a hemostatic component; number and type of blood products used until hemostasis is achieved (and randomized products are discontinued), as well as after hemostasis has been achieved, to 24 h post-admission; discharge destination and functional status and quality of life at hospital discharge or 30 days, as measured by Glasgow Coma Scale (GCS) and EuroQol (EQ-5D) quality of life measurement.
This large multicenter clinical trial will contribute high-level evidence on the effectiveness of Low-Titer Group O Whole Blood in the in-hospital management of trauma patients predicted to require a large volume transfusion. Trial registration National Clinical Trial Identified Number: NCT05638581.
https://clinicaltrials.gov/study/NCT05638581 First submitted 2022-11-08.
出血是创伤后潜在可预防死亡的最常见原因。红细胞、血浆和血小板的平衡输血(成分输血,CT)已被证明可降低死亡率,是标准治疗方法。低滴度O型全血(LTOWB)是CT的一种有吸引力的替代方案,但现有证据包括观察性研究以及一项小型单中心试点随机对照试验,该试验评估的是一种已不再使用的全血类型。“低滴度O型全血或制品用于创伤复苏”(TROOP)试验的目的是比较LTOWB和CT在预计需要大量输血的重症创伤患者中的有效性和安全性。
这是一项在美国15个一级创伤中心进行的务实、多中心、贝叶斯、序贯非劣效性/优效性随机临床试验。我们旨在将1100名受伤患者随机分为接受CT或LTOWB复苏两组。主要结局是6小时死亡率。次要结局包括24小时和30天或住院死亡率(以较早者为准);预先指定的并发症;判定的死亡原因;死亡时间;住院时间(重症监护病房和医院);以及无医院、无呼吸机和无重症监护病房天数;大手术的发生率;接受有止血成分手术的患者的止血时间;止血前(以及随机分组的制品停用前)以及止血后至入院后24小时使用的血液制品的数量和类型;出院目的地以及出院时或30天时的功能状态和生活质量,通过格拉斯哥昏迷量表(GCS)和欧洲生活质量量表(EQ-5D)进行生活质量测量。
这项大型多中心临床试验将为低滴度O型全血在预计需要大量输血的创伤患者院内管理中的有效性提供高级别证据。试验注册 国家临床试验识别号:NCT05638581。
https://clinicaltrials.gov/study/NCT05638581 首次提交时间2022年11月8日。